Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...
Condition: Cancer Survivor Interventions: Procedure: Cognitive Assessment; Other: Questionnaire Administration Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI) Recruiting
Conditions: Vertigo; Dizziness Intervention: Device: VRT Care Sponsors: Johns Hopkins University; National Institute on Deafness and Other Communication Disorders (NIDCD); GN Otometrics Recruiting
Condition: Metastatic Malignant Neoplasm in the Brain Interventions: Radiation: Single Fraction Stereotactic Radiosurgery; Radiation: Fractionated Stereotactic Radiosurgery; Procedure: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Diffuse Large B-Cell Lymphoma; Double-Expressor Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Vincristine Sulfate Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: Cardiotoxicity; HER2/Neu Positive; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Carvedilol; Other: Laboratory Biomarker Analysis; Other: Patient Observation Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Ductal Breast Carcinoma; Invasive Breast Carcinoma; Lobular Breast Carcinoma; Medullary Breast Carcinoma; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Tubular Breast Carcinoma Interventions: Radiation: Radiation Therapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment; Other: Laboratory Biomarker Analysis; Radiation: Hypofractionated Radiation Therapy Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Condition: Node Positive HER2 Negative Breast Cancer Interventions: Other: Placebo; Drug: Aspirin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group Recruiting
Conditions: Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Drug: Crizotinib; Drug: Savolitinib; Drug: Sunitinib; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Condition: Breast Carcinoma Interventions: Other: Health Education Program; Other: Weight Loss Intervention Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group Recruiting
Condition: Multiple Myeloma in Relapse Interventions: Drug: pomalidomide; Drug: ixazomib; Drug: dexamethasone Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Celgene Corporation; Millennium Pharmaceuticals, Inc. Recruiting
Condition: Lung Cancer Interventions: Radiation: Standard Radiation Dose Therapy; Drug: cisplatin; Drug: etoposide; Radiation: High Radiation Dose Therapy; Drug: carboplatin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting
Condition: Brain and Central Nervous System Tumors Interventions: Drug: concomitant temozolomide (TMZ); Radiation: radiotherapy; Drug: procarbazine; Drug: adjuvant temozolomide (TMZ); Drug: CCNU; Drug: vincristine Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); European Organisation for Research and Treatment Center (EORTC); Canadian Cancer Trials Group Recruiting
Conditions: Stage IB Breast Cancer; Stage II Breast Cancer Interventions: Radiation: regional nodal XRT; Radiation: chestwall XRT; Radiation: WBI Sponsors: NSABP Foundation Inc; National Cancer Institute (NCI); Radiation Therapy Oncology Group Recruiting
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8 Interventions: Drug: Docetaxel; Drug: Paclitaxel; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI) Recruiting
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Cancer Fatigue; Cancer Survivor; Complete Remission; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8 Interventions: Drug: Bupropion Hydrochloride Controlled-release; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: Gary Morrow; National Cancer Institute (NCI) Recruiting
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29 Interventions: Other: Usual care disease monitoring; Other: Serum Tumor Marker directed disease monitoring; Other: Quality-of-Life Assessment; Other: Anxiety Questionnaire Administration Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Condition: Stage II Prostate Adenocarcinoma Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT); Radiation: Stereotactic Body Radiation Therapy (SBRT) Sponsors: NRG Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Anxiety; Depressive Symptoms; Sleep Disturbance; Recurrent Disease; Fatigue; Quality of Life; Cancer Interventions: Other: Severe Anxiety/depression: High Intensity Stepped Care; Other: Moderate Anxiety/depression: Low Intensity Stepped care; Other: Enhanced Usual Care Control Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI) Recruiting
Conditions: Adult Grade III Lymphomatoid Granulomatosis; B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Progressive Hairy Cell Leukemia, Initial Treatment; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia Interventions: Drug: lenalidomide; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Biological: rituximab; Other: quality-of-life assessment; Other: laboratory biomarker analysis Sponsors: University of Chicago; National Cancer Institute (NCI) Recruiting
Conditions: Chronic Lymphocytic Leukemia; Plasma Cell Myeloma Interventions: Other: Medical Chart Review; Other: Interview; Other: Questionnaire; Other: Quality-of-Life Assessment Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); The Leukemia and Lymphoma Society Recruiting
Conditions: Low Back Pain; Hip Disease Interventions: Procedure: Low Back Only; Procedure: Low Back+Hip Sponsors: Temple University; University of Newcastle, Australia Recruiting
Condition: Hemophilia A Intervention: Biological: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802) Sponsors: Baxalta now part of Shire; Baxalta Innovations GmbH, now part of Shire Recruiting
Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v7; Unresectable Renal Cell Carcinoma Interventions: Drug: Ascorbic Acid; Drug: Pazopanib Hydrochloride Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI) Recruiting
Conditions: Advanced Cancer; Metastatic Cancer Interventions: Other: Patient Self-Reporting of Symptoms; Other: Usual Care Delivery Sponsors: Alliance Foundation Trials, LLC.; Patient-Centered Outcomes Research Institute; University of North Carolina; Mayo Clinic; American Society of Clinical Oncology; American Cancer Society, Inc.; Dana-Farber Cancer Institute Recruiting
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases Intervention: Other: Intense Education Intervention Sponsors: Duke University; Boehringer Ingelheim; Eli Lilly and Company Recruiting
Condition: Previously Treated Non-Small Cell Lung Cancer Intervention: Drug: Screening Platform Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Ischemic Stroke; Sleep Apnea; Sleep Apnea, Obstructive; TIA; Stroke; CPAP; Telemedicine; Home Sleep Apnea Test; Randomized Clinical Trial; Multicenter Trial Intervention: Device: CPAP Sponsors: University of Michigan; National Institute of Neurological Disorders and Stroke (NINDS); FusionHealth LLC; Medical University of South Carolina; University of Cincinnati Recruiting
Condition: Breast Cancer Interventions: Radiation: Radiation; Other: No Radiation Sponsors: Canadian Cancer Trials Group; Alliance for Clinical Trials in Oncology; Eastern Cooperative Oncology Group; NRG Oncology; Southwest Oncology Group Recruiting
Conditions: Glioblastoma; Radiotherapy; Complications; Cognitive Decline; Chemoradiation Intervention: Drug: Ramipril Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI) Recruiting
Conditions: Cerebral Vein Thrombosis; Deep Vein Thrombosis; Malignant Neoplasm; Metastatic Malignant Neoplasm; Pulmonary Embolism; Splanchnic Vein Thrombosis Intervention: Drug: Apixaban Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI) Recruiting
Condition: Heart Failure Interventions: Drug: Torsemide; Drug: Furosemide Sponsors: Duke University; National Heart, Lung, and Blood Institute (NHLBI); Yale University Recruiting
Conditions: Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Atezolizumab; Drug: Paclitaxel; Biological: Pertuzumab; Other: Placebo Administration; Other: Quality-of-Life Assessment; Biological: Trastuzumab Sponsors: National Cancer Institute (NCI); NRG Oncology Recruiting
Conditions: Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Adrenal Gland; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pancreas; Metastatic Malignant Neoplasm in the Skin; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma Interventions: Procedure: Conventional Surgery; Biological: Nivolumab; Other: Patient Observation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Condition: Chronic Heart Failure With Preserved Systolic Function Interventions: Drug: Dapagliflozin 10Mg Oral Tablet; Drug: Dapagliflozin matching placebo Sponsor: Saint Luke's Health System Recruiting
Conditions: Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: DCIS; Ductal Carcinoma in Situ Interventions: Other: Guideline Concordant Care; Other: Active Surveillance Sponsors: Alliance Foundation Trials, LLC.; Patient-Centered Outcomes Research Institute; Duke University; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; New York University; Washington University School of Medicine Recruiting
Conditions: Cognitive Dysfunction; Memory Impairment Interventions: Drug: Donepezil 5 mg; Drug: Placebo Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI) Recruiting
Conditions: Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer Interventions: Radiation: Stereotactic Radiosurgery; Procedure: Therapeutic Conventional Surgery; Other: Laboratory Biomarker Analysis Sponsors: NRG Oncology; National Cancer Institute (NCI) Recruiting
Condition: Sickle Cell Disease Intervention: Sponsors: St. Jude Children's Research Hospital; Methodist Healthcare; University of Memphis School of Public Health; Le Bonheur Children's Hospital; Methodist Adult Comprehensive Sickle Cell Center, Memphis, TN; University of Alabama at Birmingham; Washington University School of Medicine; UTHSC-ORNL Center in Biomedical Informatics; University of Washington Seattle Cancer Care Alliance; Medical College of Wisconsin; University of Tennessee Health Science Center; Children's Hospital of Philadelphia; National Heart, Lung, and Blood Institute (NHLBI) Recruiting
Condition: Eosinophilic Esophagitis Intervention: Sponsors: University of Colorado, Denver; University of Illinois at Chicago; Northwestern University; OSF St. Francis Medical Center Recruiting
Condition: Hemophilia Interventions: Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013; Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 Sponsors: American Thrombosis and Hemostasis Network; Shire; CSL Behring; Bioverativ Therapeutics Inc.; Bayer Recruiting
Conditions: Childhood Malignant Neoplasm; Cognitive Side Effects of Cancer Therapy Interventions: Procedure: Cognitive Assessment; Other: Quality-of-Life Assessment Sponsors: Children's Oncology Group; National Cancer Institute (NCI) Recruiting